The therapeutic effect of intravenous immunoglobins in several autoimmune diseases is also mediated by functional Fc receptor blockade, but these novel FcRn therapeutics demonstrate increased receptor binding affinity, which results in efficacy at a much lower dose (less than 50 mg/kg vs 1-2 g/kg body weight) (66, 67). This evidence concerns the gene FCGRT and autoimmune disease.